On November 10, 2026 BioNTech SE (Nasdaq: BNTX, "BioNTech") reported that it has entered into an agreement to acquire a US Food and Drug Administration ("FDA") Priority Review Voucher ("PRV") from Scholar Rock, Inc. (Nasdaq: SRRK, "Scholar Rock") for a total cash consideration of $205 million.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A PRV grants FDA priority review for a single application, which reduces the target FDA review timeline and could lead to expedited approval. BioNTech intends to use the PRV to support a future filing of an asset in its late-stage oncology pipeline. The transaction is subject to customary closing conditions, including clearance under the Hart-Scott Rodino ("HSR") Antitrust Improvements Act.

(Press release, BioNTech, NOV 10, 2026, View Source [SID1234674553])